Does tocilizumab mean the end of glucocorticoids in giant cell arteritis?

被引：1
|
作者：
Samson, M. [1 ,2 ,3 ]
Bonnotte, B. [1 ,2 ,3 ]
机构：
[1] CHU Dijon Bourgogne, Serv Med Interne, 2 Blvd Mal de Lattre de Tassigny, F-21000 Dijon, France
[2] CHU Dijon Bourgogne, Immunol Clin, 2 Blvd Mal de Lattre de Tassigny, F-21000 Dijon, France
[3] Univ Bourgogne Franche Comte, FHU Increase, Inserm U1098, F-21000 Dijon, France
来源：
REVUE DE MEDECINE INTERNE | 2018年 / 39卷 / 02期
关键词：
Giant cell arteritis; Treatment; Tocilizumab; LARGE-VESSEL VASCULITIS; TAKAYASU ARTERITIS; DOUBLE-BLIND; THERAPY; TRIAL; ABATACEPT;
D O I：
10.1016/j.revmed.2017.11.003
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：75 / 77
页数：3
相关论文
共 50 条
  • [31] Current advances in giant cell arteritis
    Kaushik, Megha
    Ponte, Cristina
    Mollan, Susan P.
    CURRENT OPINION IN NEUROLOGY, 2021, 34 (01) : 133 - 141
  • [32] Clinical and biological efficacy of tocilizumab in giant cell arteritis: Report of three patients and literature review
    Kieffer, P.
    Hinschberger, O.
    Ciobanu, E.
    Jaeger-Bizet, F.
    Drabo, A.
    Mostoufizadeh, T.
    Martzolff, L.
    REVUE DE MEDECINE INTERNE, 2014, 35 (01): : 56 - 59
  • [33] Does leflunomide have a role in giant cell arteritis? An open-label study
    Hocevar, Alojzija
    Jese, Rok
    Rotar, Ziga
    Tomsic, Matija
    CLINICAL RHEUMATOLOGY, 2019, 38 (02) : 291 - 296
  • [34] Magnetic resonance angiography in giant cell arteritis: results of a randomized controlled trial of tocilizumab in giant cell arteritis
    Reichenbach, Stephan
    Adler, Sabine
    Bonel, Harald
    Cullmann, Jennifer L.
    Kuchen, Stefan
    Butikofer, Lukas
    Seitz, Michael
    Villiger, Peter M.
    RHEUMATOLOGY, 2018, 57 (06) : 982 - 986
  • [35] Efficacy of tocilizumab in refractory giant cell arteritis
    Vinit, Julien
    Bielefeld, Philip
    Muller, Geraldine
    Besancenot, Jean-Francois
    JOINT BONE SPINE, 2012, 79 (03) : 317 - 318
  • [36] Trial of Tocilizumab in Giant-Cell Arteritis
    Stone, J. H.
    Tuckwell, K.
    Dimonaco, S.
    Klearman, M.
    Aringer, M.
    Blockmans, D.
    Brouwer, E.
    Cid, M. C.
    Dasgupta, B.
    Rech, J.
    Salvarani, C.
    Schett, G.
    Schulze-Koops, H.
    Spiera, R.
    Unizony, S. H.
    Collinson, N.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (04) : 317 - 328
  • [37] Giant cell arteritis with ocular involvement successfully treated with tocilizumab and very short-course glucocorticoids: A case report
    Khanna, R. K.
    Hage, R.
    Lecler, A.
    Sene, T.
    Vignal-Clermont, C.
    Clavel-Refregiers, G.
    JOURNAL FRANCAIS D OPHTALMOLOGIE, 2021, 44 (04): : 481 - 484
  • [38] Effectiveness of a two-year tapered course of tocilizumab in patients with giant cell arteritis: A single-centre prospective study
    Tomelleri, Alessandro
    Campochiaro, Corrado
    Farina, Nicola
    Mariotti, Letizia
    Baldissera, Elena
    Grayson, Peter C.
    Matucci-Cerinic, Marco
    Dagna, Lorenzo
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2023, 59
  • [39] Effectiveness Of Tocilizumab In Aortitis And Aneurysms Associated With Giant Cell Arteritis
    Martin-Gutierrez, Adrian
    Loricera, Javier
    Narvaez, Javier
    Aldasoro, Vicente
    Maiz, Olga
    Vela, Paloma
    Romero-Yuste, Susana
    de Miguel, Eugenio
    Galindez-Agirregoikoa, Eva
    Fernandez-Lopez, Jesus C.
    Ferraz-Amaro, Ivan
    Sanchez-Martin, Julio
    Moya, Patricia
    Campos, Cristina
    Lopez-Gutierrez, Fernando
    Castaneda, Santos
    Blanco, Ricardo
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2024, 129 : 78 - 86
  • [40] Use of 18F-fluorodeoxyglucose positron emission tomography to monitor tocilizumab effect on vascular inflammation in giant cell arteritis
    Quinn, Kaitlin A.
    Dashora, Himanshu
    Novakovich, Elaine
    Ahlman, Mark A.
    Grayson, Peter C.
    RHEUMATOLOGY, 2021, 60 (09) : 4384 - 4389
12345